These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 15708050

  • 1. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ, Roobol DW, Schröder FH.
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [Abstract] [Full Text] [Related]

  • 2. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH, Bangma CH, Roobol MJ.
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [Abstract] [Full Text] [Related]

  • 3. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [Abstract] [Full Text] [Related]

  • 9. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ.
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [Abstract] [Full Text] [Related]

  • 10. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
    Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG, Pileblad E.
    J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
    [Abstract] [Full Text] [Related]

  • 11. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
    Gonzalez CM, Roehl KA, Antenor JV, Blunt LW, Han M, Catalona WJ.
    Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
    [Abstract] [Full Text] [Related]

  • 12. Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program.
    Varkarakis J, Pinggera GM, Sebe P, Berger A, Bartsch G, Horninger W.
    Urology; 2004 Feb; 63(2):337-41. PubMed ID: 14972485
    [Abstract] [Full Text] [Related]

  • 13. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R, de Vries SH, Blijenberg BG, Wildhagen MF, Postma R, Bangma CH, Darte C, Schröder FH.
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [Abstract] [Full Text] [Related]

  • 14. Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Luján M, Páez A, Pascual C, Angulo J, Miravalles E, Berenguer A.
    Eur Urol; 2006 Dec; 50(6):1234-40; discussion 1239-40. PubMed ID: 16704893
    [Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
    Welch HG, Schwartz LM, Woloshin S.
    J Natl Cancer Inst; 2005 Aug 03; 97(15):1132-7. PubMed ID: 16077071
    [Abstract] [Full Text] [Related]

  • 16. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
    Ito K, Kubota Y, Yamamoto T, Suzuki K, Fukabori Y, Kurokawa K, Yamanaka H.
    Cancer; 2001 Feb 15; 91(4):744-51. PubMed ID: 11241242
    [Abstract] [Full Text] [Related]

  • 17. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
    Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H.
    Prostate; 2003 Sep 15; 57(1):8-13. PubMed ID: 12886518
    [Abstract] [Full Text] [Related]

  • 18. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    Loeb S, Nadler RB, Roehl KA, Antenor JA, Catalona WJ.
    J Urol; 2007 May 15; 177(5):1745-8. PubMed ID: 17437803
    [Abstract] [Full Text] [Related]

  • 19. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.
    Candas B, Labrie F, Gomez JL, Cusan L, Chevrette E, Lévesque J, Brousseau G.
    J Urol; 2006 Feb 15; 175(2):510-6; discussion 516-7. PubMed ID: 16406983
    [Abstract] [Full Text] [Related]

  • 20. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
    Bourel M, Ardaillou R, Académie nationale de médecine.
    Bull Acad Natl Med; 2003 Feb 15; 187(5):985-95. PubMed ID: 14979060
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.